Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Shih-Kai Hung, Hsuan-Ju Yang, Moon-Sing Lee, Dai-Wei Liu, Liang-Cheng Chen, Chia-Hui Chew, Chun-Hung Lin, Cheng-Hung Lee, Szu-Chin Li, Chung-Lin Hong, Chih-Chia Yu, Ben-Hui Yu, Feng-Chun Hsu, Wen-Yen Chiou, Hon-Yi Lin
BACKGROUND: Based on the molecular expression of cancer cells, molecular subtypes of breast cancer have been applied to classify patients for predicting clinical outcomes and prognosis. However, further evidence is needed regarding the influence of molecular subtypes on the efficacy of radiotherapy (RT) after breast-conserving surgery (BCS), particularly in a population-based context. Hence, the present study employed a propensity-score-matched cohort design to investigate the potential role of molecular subtypes in stratifying patient outcomes for post-BCS RT and to identify the specific clinical benefits that may emerge...
December 8, 2023: Breast Cancer Research: BCR
#22
JOURNAL ARTICLE
Michaela Stenckova, Yajing Liu, Marta Nekulova, Jitka Holcakova, Zuzana Pokorna, Rudolf Nenutil, Alastair M Thompson, Borivoj Vojtesek, Philip John Coates
Breast cancers are a heterogeneous group of tumors classified according to their histological growth patterns and receptor expression characteristics. Intratumor heterogeneity also exists, with subpopulations of cells with different phenotypes found in individual cancers, including cells with stem or progenitor cell properties. At least two types of breast cancer stem cells (CSCs) exist, the epithelial and the basal/mesenchymal subtypes, although how these phenotypes are controlled is unknown. ΔNp63 is a basal cell marker and regulator of stem/progenitor cell activities in the normal mammary gland and is expressed in the basal-like CSC subpopulation in some estrogen receptor-positive (ER+) and/or human epidermal growth factor receptor 2-positive (HER2+) breast adenocarcinomas...
October 2023: Neoplasma
#23
JOURNAL ARTICLE
Menghan Liu, Shuai Zhang, Yanan Du, Xiaodong Zhang, Dawei Wang, Wanqing Ren, Jingxiang Sun, Shiwei Yang, Guang Zhang
PURPOSE: To evaluate the diagnostic performance of a deep learning model based on multi-modal images in identifying molecular subtype of breast cancer. MATERIALS AND METHODS: A total of 158 breast cancer patients (170 lesions, median age, 50.8 ± 11.0 years), including 78 Luminal A subtype and 92 non-Luminal A subtype lesions, were retrospectively analyzed and divided into a training set (n = 100), test set (n = 45), and validation set (n = 25). Mammography (MG) and magnetic resonance imaging (MRI) images were used...
2023: Frontiers in Oncology
#24
JOURNAL ARTICLE
Anupama Praveen Kumar, Diego Vicente, Jianfang Liu, Praveen-Kumar Raj-Kumar, Brenda Deyarmin, Xiaoying Lin, Craig D Shriver, Hai Hu
PURPOSE: To explore the association of clinicopathologic and molecular factors with the occurrence of positive margins after first surgery in breast cancer. METHODS: The clinical and RNA-Seq data for 951 (75 positive and 876 negative margins) primary breast cancer patients from The Cancer Genome Atlas (TCGA) were used. The role of each clinicopathologic factor for margin prediction and also their impact on survival were evaluated using logistic regression, Fisher's exact test, and Cox proportional hazards regression models...
December 1, 2023: Breast Cancer Research and Treatment
#25
JOURNAL ARTICLE
Zhangxiang Zhao, Tongzhu Jin, Bo Chen, Qi Dong, Mingyue Liu, Jiayu Guo, Xiaoying Song, Yawei Li, Tingting Chen, Huiming Han, Haihai Liang, Yunyan Gu
Identifying robust breast cancer subtypes will help to reveal the cancer heterogeneity. However, previous breast cancer subtypes were based on population-level quantitative gene expression, which is affected by batch effects and cannot be applied to individuals. We detected differential gene expression, genomic, and epigenomic alterations to identify driver differential expression at the individual level. The individual driver differential expression reflected the breast cancer patients' heterogeneity and revealed four subtypes...
November 16, 2023: Cell Cycle
#26
JOURNAL ARTICLE
Xingchen Li, Guidong Chen, Fanchen Wang, Xiaojing Guo, Rui Zhang, Pengpeng Liu, Li Dong, Wenwen Yu, Huan Wang, Hailong Wang, Jinpu Yu
BACKGROUND: Oncogenic PIK3CA mutations (PIK3CAmut ) frequently occur in a higher proportion in luminal breast cancer (LBC), especially in refractory advanced cases, and are associated with changes in tumour cellular metabolism. Nevertheless, its effect on the progression of the immune microenvironment (TIME) within tumours and vital molecular events remains veiled. METHODS: Multiplex immunohistochemistry (mIHC) and single-cell mass cytometry (CyTOF) was used to describe the landscape of TIME in PIK3CAmut LBC...
November 2023: Clinical and Translational Medicine
#27
Michael D Iglesia, Reyka G Jayasinghe, Siqi Chen, Nadezhda V Terekhanova, John M Herndon, Erik Storrs, Alla Karpova, Daniel Cui Zhou, Nataly Naser Al Deen, Andrew T Shinkle, Rita Jui-Hsien Lu, Wagma Caravan, Andrew Houston, Yanyan Zhao, Kazuhito Sato, Preet Lal, Cherease Street, Fernanda Martins Rodrigues, Austin N Southard-Smith, André Luiz N Targino da Costa, Houxiang Zhu, Chia-Kuei Mo, Lisa Crowson, Robert S Fulton, Matthew A Wyczalkowski, Catrina C Fronick, Lucinda A Fulton, Hua Sun, Sherri R Davies, Elizabeth L Appelbaum, Sara E Chasnoff, Madelyn Carmody, Candace Brooks, Ruiyang Liu, Michael C Wendl, Clara Oh, Diane Bender, Carlos Cruchaga, Oscar Harari, Andrea Bredemeyer, Kory Lavine, Ron Bose, Julie Margenthaler, Jason M Held, Samuel Achilefu, Foluso Ademuyiwa, Rebecca Aft, Cynthia Ma, Graham A Colditz, Tao Ju, Stephen T Oh, James Fitzpatrick, E Shelley Hwang, Kooresh I Shoghi, Milan G Chheda, Deborah J Veis, Feng Chen, Ryan C Fields, William E Gillanders, Li Ding
Breast cancer is a heterogeneous disease, and treatment is guided by biomarker profiles representing distinct molecular subtypes. Breast cancer arises from the breast ductal epithelium, and experimental data suggests breast cancer subtypes have different cells of origin within that lineage. The precise cells of origin for each subtype and the transcriptional networks that characterize these tumor-normal lineages are not established. In this work, we applied bulk, single-cell (sc), and single-nucleus (sn) multi-omic techniques as well as spatial transcriptomics and multiplex imaging on 61 samples from 37 breast cancer patients to show characteristic links in gene expression and chromatin accessibility between breast cancer subtypes and their putative cells of origin...
November 2, 2023: bioRxiv
#28
JOURNAL ARTICLE
Witali Aswolinskiy, Enrico Munari, Hugo M Horlings, Lennart Mulder, Giuseppe Bogina, Joyce Sanders, Yat-Hee Liu, Alexandra W van den Belt-Dusebout, Leslie Tessier, Maschenka Balkenhol, Michelle Stegeman, Jeffrey Hoven, Jelle Wesseling, Jeroen van der Laak, Esther H Lips, Francesco Ciompi
BACKGROUND: Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy; however, only a fraction of the patients respond to it completely. To prevent overtreatment, there is an urgent need for biomarkers to predict treatment response before administering the therapy. METHODS: In this retrospective study, we developed hypothesis-driven interpretable biomarkers based on deep learning, to predict the pathological complete response (pCR, i...
November 13, 2023: Breast Cancer Research: BCR
#29
RANDOMIZED CONTROLLED TRIAL
Sara M Tolaney, Shom Goel, Jorge Nadal, Hannelore Denys, Manuel R Borrego, Lacey M Litchfield, Jiangang Liu, Adams K Appiah, Yanyun Chen, Fabrice André
PURPOSE: The monarcHER trial has shown that abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, combined with fulvestrant and trastuzumab, improves progression-free survival (PFS) in hormone receptor-positive (HR+), HER2-positive (HER2+) advanced breast cancer (ABC) compared with standard-of-care (SOC) chemotherapy combined with trastuzumab. We report the final overall survival (OS) analysis, updated safety and efficacy data, and exploratory biomarker results from monarcHER. PATIENTS AND METHODS: monarcHER (NCT02675231), a randomized, multicenter, open-label, phase II trial, enrolled 237 patients across Arm A (abemaciclib, trastuzumab, fulvestrant), Arm B (abemaciclib, trastuzumab), and Arm C (SOC chemotherapy, trastuzumab)...
January 5, 2024: Clinical Cancer Research
#30
JOURNAL ARTICLE
Hua-Tao Wu, Zheng Wu, Yan-Yu Hou, Ze-Xuan Fang, Bing-Xuan Wu, Yu Deng, Yu-Kun Cui, Jing Liu
Aim: To investigate SIX4 in breast cancer. Methods: Publicly available online tools were used to analyze the expression, methylation and prognostic significance of SIX4 in breast cancer, as well as its immunohistochemistry. Results: High SIX4 levels were associated with low SIX4 promoter methylation, especially in estrogen receptor-positive breast cancer. Increased SIX4 was related to advanced stage and decreased immune infiltration. Gene set enrichment analysis found that the SIX4 -correlated genes were enriched in transcriptional processing and immune response...
October 31, 2023: Epigenomics
#31
JOURNAL ARTICLE
UTP23 Functions in Breast Cancer Progression and Predicts Poor Prognosis of Luminal a Breast Cancer.
Sida Zhang, Xiaoyu Bai, Fan Li, Chunsheng Ni, Yanlei Li, Na Che, Nan Zhao, Xiulan Zhao, Tieju Liu
BACKGROUND: Luminal A breast cancer is the most common molecular subtype of breast cancer. Exploring biomarkers to identify luminal A breast cancer patients at high risk of recurrence and metastasis has important clinical significance. UTP23 is a component of ribosomal small-subunit processome, which is involved in ribosome synthesis and RNA maturation. The role of UTP23 in breast cancer has not been reported. METHODS: TCGA-BRCA data, LinkedOmics, STRING, Metascape and ssGSEA were used to analyze UTP23 expression in breast cancer and evaluate prognosis...
October 4, 2023: Clinical Breast Cancer
#32
JOURNAL ARTICLE
Yu-Ching Hsu, Hung-Lin Chen, Chi-Fung Cheng, Amrita Chattopadhyay, Pei-Shan Chen, Che-Chen Lin, Hsiu-Yin Chiang, Ting-Yuan Liu, Chi-Hao Huang, Chin-Chi Kuo, Eric Y Chuang, Tzu-Pin Lu, Fuu-Jen Tsai
PURPOSE: Breast cancer is a molecularly heterogeneous disease, and multiple genetic variants contribute to its development and prognosis. Most of previous genome-wide association studies (GWASs) and polygenic risk scores (PRSs) analyses focused on studying breast cancers of Caucasian populations, which may not be applicable to other population. Therefore, we conducted the largest breast cancer cohort of Taiwanese population to fill in the knowledge gap. METHODS: A total of 152,534 Participants recruited by China Medical University Hospital between 2003 and 2019 were filtered by several patient selection criteria and GWAS quality control steps, resulting in the inclusion of 2496 cases and 9984 controls for this study...
October 18, 2023: Breast Cancer Research and Treatment
#33
JOURNAL ARTICLE
Yaqi Qiu, Hui Wang, Qian Guo, Yiwen Liu, Yiqing He, Guoliang Zhang, Cuixia Yang, Yan Du, Feng Gao
Some cancer cells migration and metastasis are characterized by the outgrowth of lamellipodia protrusions in which the underlying mechanism remains unclear. Evidence has confirmed that lamellipodia formation could be regulated by various adhesion molecules, such as CD44, and we previously reported that lamellipodia at the leading edge of luminal type breast cancer (BrCa) were enriched with high expression of CD44. In this study, we found that the overexpression of CD44s could promote lamellipodia formation in BrCa cells through inducing tissue type plasminogen activator (tPA) upregulation, which was achieved by PI3K/Akt signaling pathway activation...
2023: Frontiers in Cell and Developmental Biology
#34
JOURNAL ARTICLE
Xi Jin, Yi-Fan Zhou, Ding Ma, Shen Zhao, Cai-Jin Lin, Yi Xiao, Tong Fu, Cheng-Lin Liu, Yi-Yu Chen, Wen-Xuan Xiao, Ya-Qing Liu, Qing-Wang Chen, Ying Yu, Le-Ming Shi, Jin-Xiu Shi, Wei Huang, John F R Robertson, Yi-Zhou Jiang, Zhi-Ming Shao
Hormone receptor-positive (HR+ )/human epidermal growth factor receptor 2-negative (HER2- ) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding precision treatment. We established a large-scale multi-omics cohort of 579 patients with HR+ /HER2- breast cancer and identified the following four molecular subtypes: canonical luminal, immunogenic, proliferative and receptor tyrosine kinase (RTK)-driven...
October 2023: Nature Genetics
#35
Ashuvinee Elangovan, Emily A Bossart, Ahmed Basudan, Nilgun Tasdemir, Osama Shiraz Shah, Kai Ding, Carolin Meier, Tanya Heim, Carola Neumann, Shireen Attaran, Lauren Brown, Jagmohan Hooda, Lori Miller, Tiantong Liu, Shannon L Puhalla, Grzegorz Gurda, Peter C Lucas, Priscilla F McAuliffe, Jennifer M Atkinson, Adrian V Lee, Steffi Oesterreich
UNLABELLED: Breast cancer is categorized by the molecular and histologic presentation of the tumor, with the major histologic subtypes being No Special Type (NST) and Invasive Lobular Carcinoma (ILC). ILC are characterized by growth in a single file discohesive manner with stromal infiltration attributed to their hallmark pathognomonic loss of E-cadherin ( CDH1 ). Few ILC cell line models are available to researchers. Here we report the successful establishment and characterization of a novel ILC cell line, WCRC-25, from a metastatic pleural effusion from a postmenopausal Caucasian woman with metastatic ILC...
September 17, 2023: bioRxiv
#36
JOURNAL ARTICLE
Xinming Song, Pintian Wang, Ruiling Feng, Mandika Chetry, E Li, Xiaohua Wu, Zewa Liu, Shasha Liao, Jing Lin
PURPOSE: To study the clinicopathological variables connected with disease-free survival (DFS) as well as overall survival (OS) in patients who are ER-positive or HER2-negative and to propose nomograms for predicting individual risk. METHODS: In this investigation, we examined 585 (development cohort) and 291 (external validation) ER-positive, HER2-negative breast cancer patients from January 2010 to January 2014. From January 2010 to December 2014, we retrospectively reviewed and analyzed 291 (external validation) and 585 (development cohort) HER2-negative, ER-positive breast cancer patients...
September 15, 2023: Clinical & Translational Oncology
#37
JOURNAL ARTICLE
Wen-Yi Yue, Hong-Tao Zhang, Shen Gao, Guang Li, Ze-Yu Sun, Zhe Tang, Jian-Ming Cai, Ning Tian, Juan Zhou, Jing-Hui Dong, Yuan Liu, Xu Bai, Fu-Geng Sheng
OBJECTIVE: The aim of the study is to demonstrate whether radiomics based on an automatic segmentation method is feasible for predicting molecular subtypes. METHODS: This retrospective study included 516 patients with confirmed breast cancer. An automatic segmentation-3-dimensional UNet-based Convolutional Neural Networks, trained on our in-house data set-was applied to segment the regions of interest. A set of 1316 radiomics features per region of interest was extracted...
September 2023: Journal of Computer Assisted Tomography
#38
JOURNAL ARTICLE
Liyang Yin, Renxian Cao, Zhuoqing Liu, Gang Luo, Yu Li, Xiaolong Zhou, Xiguang Chen, Ying Wu, Jun He, Xuyu Zu, Yingying Shen
Triple-negative breast cancer (TNBC) lacks effective therapeutic targets and has a poor prognosis, easy recurrence and metastasis. It is urgent and important to explore TNBC treatment targets. Through mass spectrometry combined with qRT-PCR validation in luminal A cells and TNBC cells, high-content screening and clinical sample analysis, FUNDC2 was discovered as a novel target. The function of the outer mitochondrial membrane protein FUNDC2 in breast cancer is still unclear. In this study, we find that FUNDC2 expression in TNBC tissues is significantly higher than that in luminal subtype breast cancer tissues...
September 12, 2023: Acta Biochimica et Biophysica Sinica
#39
JOURNAL ARTICLE
Huina Wang, Bo Liu, Junqi Long, Jiangyong Yu, Xinchan Ji, Jinmeng Li, Nian Zhu, Xujie Zhuang, Lujia Li, Yuhaoran Chen, Zhidong Liu, Shu Wang, Shuangtao Zhao
Comprehensive multiplatform analysis of Luminal B breast cancer (LBBC) specimens identifies two molecularly distinct, clinically relevant subtypes: Cluster A associated with cell cycle and metabolic signaling and Cluster B with predominant epithelial mesenchymal transition (EMT) and immune response pathways. Whole-exome sequencing identified significantly mutated genes including TP53 , PIK3CA , ERBB2 , and GATA3 with recurrent somatic mutations. Alterations in DNA methylation or transcriptomic regulation in genes ( FN1 , ESR1 , CCND1 , and YAP1 ) result in tumor microenvironment reprogramming...
September 15, 2023: IScience
#40
JOURNAL ARTICLE
Lina Zhang, Tiantian Tang, Lei Liu, Chunxiao Li, Yuntao Li, Cuizhi Geng
BACKGROUND: Currently, it remains unclear regarding the association between tumor-infiltrating lymphocytes (TILs) and the efficacy of postoperative radiotherapy in primary tumors. Here we attempted to investigate the effect of TILs depending on the presence of postmastectomy radiotherapy (PMRT) on the prognosis in pT1-2N1M0 breast cancer. METHODS: The clinical data of pT1-2N1M0 breast cancer patients undergoing mastectomy and axillary lymph node dissection were retrospectively analyzed...
2023: Frontiers in Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
